



LEVERAGE

Follow-On Funding From the
National Institutes of Health for 2021
Cure Alzheimer's Fund Research Grants



Cure Alzheimer's FUND

20 years of breakthrough research

“ ”

The emphasis on basic knowledge is absolutely critical. The tendency is to be driven by urgency which leads you to take any possible avenue, and that is a dangerous approach that leads to short-cuts, guesses, and applying investment dollars with no true underlying understanding. It also moves people away from the long-term research that is necessary.

—DAVID BALTIMORE, PH.D., NOBEL LAUREATE,
NOBEL PRIZE FOR PHYSIOLOGY OR MEDICINE

“ ”

Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.

—ARCHIMEDES

OUR FOUNDING PRINCIPLES

The founders of Cure Alzheimer's Fund (CureAlz) embraced as a core tenet that the best way to accelerate potential therapies for Alzheimer's disease is to support fundamental proof-of-concept research into its causes. Established ideas and orthodox approaches to research attract funding within the traditional system. However, scientists with well-reasoned but unique or unconventional ideas regarding the contributing factors to Alzheimer's disease struggle to obtain the financing necessary to test their hypotheses. Cure Alzheimer's Fund takes bold, smart risks on promising early research, and the knowledge learned from these projects is shared with the entire field. Once validated through our grants, these ideas may receive follow-on funding from the National Institutes of Health / National Institute on Aging (NIH / NIA) and other institutions far beyond what our resources alone can provide.

A second and equally important tenet is the importance of advancing the entire field even though CureAlz can fund only a select group of investigators. CureAlz provides funding for research intended to be shared with and published to the scientific community and requires open communication and collaboration across its network of funded and affiliated researchers. As a result, every project returns benefits far beyond the advancement of just one lab or just one proprietary molecule. Similarly, the animal models commissioned by CureAlz are available to all scientific labs, not only to projects we fund.

The advantages achieved with substantial follow-on funding, science sharing, and collaboration are considerable. We thank our very generous donors who have made these investments possible and our researchers who have been truly remarkable and passionate leaders in the commitment to finding a cure for Alzheimer's disease.

\$16.7 million in CureAlz research in 2021 led to \$128 million from the National Institutes of Health.

7.7 X

RETURN ON INVESTMENT
FOR 2021

\$64 million for 2018-2021 yielded \$497 million in funding from the National Institutes of Health.


Our grants for proof-of-concept research provide the necessary data and derisking, leading to follow-on funding from the National Institutes of Health (NIH) / National Institute on Aging (NIA) and other investors. As an illustration of this strength, our 2021 research portfolio with distributions totaling \$16.7 million led to additional funding from the NIH / NIA of \$128 million, a return of 7.7X.

For the combined years of 2018 through 2021, the total of \$64 million in grants provided to researchers from Cure Alzheimer's Fund resulted in an extraordinary \$497 million of follow-on funding from NIH / NIA.

For the three years of 2018 through 2021 combined, the return of follow-on funding from the NIH / NIA is 7.8X.

CUREALZ GRANT INVESTMENTS AND RELATED NIH FUNDING TO CUREALZ SUPPORTED INVESTIGATORS

	CURE ALZHEIMER'S FUND TOTAL	NIH TOTAL
FOUNDATIONAL RESEARCH		
GENETIC RISK FACTORS	\$1,739,496	\$3,104,135
BIOMARKERS, DIAGNOSTICS, AND STUDIES OF RISK AND RESILIENCE	\$300,000	\$0
BIOLOGICAL RESEARCH MATERIALS: NEW ANIMAL AND CELLULAR MODELS AND HUMAN SAMPLES	\$207,550	\$4,323,328
EPIGENETIC FACTORS	\$1,666,876	\$38,537,445
TRANSLATIONAL RESEARCH		
STUDIES OF NOVEL ALZHEIMER'S DISEASE GENES	\$690,000	\$2,063,098
STUDIES OF AMYLOID PRECURSOR PROTEIN (APP) AND AMYLOID BETA	\$766,993	\$6,176,729
STUDIES OF TAU	\$594,789	\$3,938,401
STUDIES OF APOLIPOPROTEIN E (APOE)	\$2,085,558	\$15,135,147
STUDIES OF THE IMMUNE RESPONSE IN ALZHEIMER'S DISEASE	\$3,582,099	\$27,609,399
STUDIES OF ALTERNATIVE NEURODEGENERATIVE PATHWAYS	\$2,781,301	\$20,774,563
DRUG DISCOVERY AND ENABLING TECHNOLOGIES		
DRUG SCREENING AND LEAD DRUG EVALUATION PROJECTS	\$1,804,214	\$6,822,570
DRUG DELIVERY AND ENABLING TECHNOLOGIES	\$172,500	\$0
PRECLINICAL AND CLINICAL DRUG DEVELOPMENT AND TRIALS		
PRECLINICAL DRUG DEVELOPMENT	\$291,374	\$0
CLINICAL TRIALS	\$78,234	\$0
CLINICAL TRIAL DESIGN	\$0	\$0



73,603

DONORS

95

FUNDED
INSTITUTIONS

814

RESEARCH
PROJECTS

1182

PAPERS
PUBLISHED

297

FUNDED
RESEARCHERS

98,998

PAPER
CITATIONS

\$193,000,000

IN RESEARCH

As of December 2023





SUPPORT OUR RESEARCH

ONLINE

You can donate directly from our website—please visit:
www.CureAlz.org/Giving/Donate.

MAIL

If you prefer to make a donation by personal check, please make your check payable to: Cure Alzheimer's Fund. Our address is: Cure Alzheimer's Fund, 34 Washington St., Suite 310, Wellesley Hills, MA 02481.

TELEPHONE

If you would like to make a donation by telephone, please call us at 781-237-3800. Our business hours are 9 a.m. to 5 p.m. ET. When calling after hours, please leave a message and we will return your call the next business day.

DONOR ADVISED FUNDS

Donors with funds held by Fidelity Charitable, Schwab Charitable or Great Kansas Community Foundation may use the DAF Direct form on our website at www.CureAlz.org/giving/donate to process donations. For all other Donor Advised Fund holders, please mail checks to our office at: Cure Alzheimer's Fund, 34 Washington St., Suite 310, Wellesley Hills, MA 02481.

PLANNED GIVING

We offer a number of planned giving options, some of which may provide tax incentives. These include bequests, qualified charitable distributions (QCDs), charitable gift annuities, charitable remainder trusts (CRTs), charitable lead trusts (CLTs) and gifts of retirement assets or life insurance policies.

To explore these and other ways to give, please visit:
www.CureAlz.org/Giving/Donate/
or contact Laurel Lyle at LLyle@CureAlz.org,
or call 781-237-3800.



RECOGNIZED FOR EXCELLENCE



Charity Navigator awarded Cure Alzheimer's Fund its highest rating of four stars, and has listed the organization in the top three percent of all charities for twelve consecutive years.



GuideStar lists Cure Alzheimer's Fund as a platinum-level participant—its highest level of recognition.



Cure Alzheimer's Fund is an accredited charity and meets all 20 of the Better Business Bureau's standards for charity accountability.

100% of all general donations go to support our research.

Our Founders, Board of Directors, Trustees, and a core group of other donors pay all overhead expenses.



WWW.CUREALZ.ORG

34 Washington Street · Suite 310 · Wellesley Hills, Massachusetts 02481 · 781-237-3800

Cure Alzheimer's Fund is a "doing business as" name for the Alzheimer's Disease Research Foundation, a 501(c)(3) public charity with federal tax ID #52-239-6428